Randolph Corteling, our Chief Scientific Officer, presented at the event on Tuesday 14 March. His presentation entitled – ‘CustomEXTM a new stem cell-derived drug delivery platform’, highlighted the advantages of ReNeuron’s customisable stem-cell derived exosome drug delivery platform (CustomEXTM) over current technologies.
The presentation can be viewed by clicking here.
ReNeuron Group PLC (AIM:RENE, OTC:RNUGF) executive chairman Iain Ross tells Proactive that the company is focused on generating in vivo data and validating its exosome delivery technology platform CustomEX as 2023 gets underway.
19 January 2023: ReNeuron Group plc (AIM: RENE), a UK-based R&D organisation focused on stem-cell derived exosome delivery technologies, announces that further to the announcement of 3 January 2023, the Company has undertaken a restructuring of the business. Headcount has been reduced by 40%, the overall variable costs of the business lowered and, as a result, the cash runway now extends into 2024 with all resources being directed towards generating in vivo data and validating the Company’s exosome delivery technology platform CustomEX™.
Iain Ross appointed as Executive Chairman, CEO steps down
03 January 2023: ReNeuron Group plc (AIM: RENE), a UK-based leader in stem cell-derived exosome technologies, announces that Catherine Isted, ACMA, Chief Executive Officer (“CEO”) has stepped down from her role with immediate effect.
Iain Ross, who has been on the Board since July 2021, has been appointed as Executive Chairman and will lead a restructuring of the business, with further announcements to be made in due course.
ReNeuron presents new data highlighting the advantages of its novel type of iPSCs including data from the Company’s collaboration with University College London
08 December 2022: ReNeuron Group plc (AIM: RENE), a UK-based leader in stem cell derived exosomes technologies, announces that one of its lead scientists, Dr Steve Pells, yesterday presented new data on the advantages of its induced pluripotent stem cells (iPSCs) including data from the Company’s collaboration with University College London (UCL), at a major industry conference on iPSC-Derived Cell Therapies.
02 December 2022: ReNeuron Group plc (AIM: RENE), a UK based leader in Stem Cell derived Exosome Technologies, announces its unaudited interim results for the six months ended 30 September 2022 and a funding update.
ReNeuron Group plc (AIM: RENE), a UK-based leader in stem cell derived exosomes technologies, announces that the Company’s CSO, Dr Randolph Corteling, has presented new data at the Extracellular Vesicle-Based Therapeutic Development Summit in Boston, MA, highlighting the significant advantages of the Company’s stem cell derived exosome approach.
ReNeuron Group plc (AIM: RENE), a UK-based leader in stem cell derived exosome technologies, announces the appointment of John Hawkins, ACA, as Chief Financial Officer (‘CFO’) and ReNeuron Board member with immediate effect. The Group is also pleased to announce that Simon Dew will be joining the Executive Team as Chief Business Officer (‘CBO’).
Additionally, the Group is making changes to the Executive team.
ReNeuron Group plc (AIM: RENE), a UK-based leader in stem cell derived exosome technologies, announces that at the Annual General Meeting (AGM) held earlier today, all resolutions were duly passed.
ReNeuron Group plc (AIM: RENE), a UK-based stem cell leader in stem cell derived exosome technologies, announces that its Annual Report and Accounts for the year ended 31 March 2022 and the Notice of the 2022 Annual General Meeting (“AGM”) have today been sent to shareholders and are also available on the Company’s website.
